IntelliPharmaCeutics International Inc. (IPCI)

Check out top investors' recommendation for IPCI
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
2.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. It has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, and pain. The company’s products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorder; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux disease; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorder, and depressive disorder; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as product filed with the FDA comprise Pristiq, a tablet for depression. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Its late stage development product includes Coreg CR, a capsule for heart failure and hypertension; and phase I clinical trial products include Lyrica, a capsule for Neuropathic pain and Oxycodone Hydrochloride, a controlled release capsule for pain. The company’s non-generic products under development include Rexista, an oral formulation for pain relief, and Pregabalin, an extended release capsule for neuropathic pain. The company was founded in 1998 and is based in Toronto, Canada.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ram Selvaraju Aegis Capital Buy   May 29, '18     2.50  May 29, '19  N/A 
Ram Selvaraju Aegis Capital Buy   Mar 05, '18     2.50  Mar 05, '19  N/A 
Jason Kolbert Maxim Group Buy   Jan 26, '18     2.00  Jan 26, '19  N/A 
Ram Selvaraju Aegis Capital Buy   Jan 19, '18     2.50  Jan 19, '19  N/A 
Jason Kolbert Maxim Group Buy   Sep 25, '17     2.00  Sep 25, '18  N/A 
Jason Kolbert Maxim Group Buy   Jul 21, '17     6.00  Jul 21, '18  N/A 
Jason Kolbert Maxim Group Buy   Dec 31, '15   2.02  6.00  Dec 31, '16  40.59% 
Jason Kolbert Maxim Group Buy   Oct 09, '15   1.80  8.00  Oct 09, '16  32.22% 
Jonathan Aschoff Brean Murray, Carret & Co. Buy   Oct 09, '15   1.80  8.00  Oct 09, '16  32.22% 
Jonathan Aschoff Brean Murray, Carret & Co. Buy   Jul 14, '15   3.67    Jul 14, '16  -56.95% 
Jonathan Aschoff Brean Murray, Carret & Co. Buy   Mar 31, '15   2.79    Mar 31, '16  -26.88% 
Jonathan Aschoff Brean Murray, Carret & Co. Buy   Feb 03, '15   2.30    Feb 03, '16  0.87% 
Jonathan Aschoff Brean Murray, Carret & Co. Buy   Oct 16, '14   2.72    Oct 16, '15  -31.99% 
Jason Kolbert Maxim Group Buy   Sep 05, '14   3.14    Sep 05, '15  -29.62% 
Jonathan Aschoff Brean Murray, Carret & Co. Buy   Sep 10, '12   2.86  7.00  Sep 10, '13  -36.01% 
Kevin Degeeter Ladenburg Thalmann & Co. Buy   Oct 10, '11   3.07  7.00  Oct 10, '12  -0.65% 
Kevin Degeeter Ladenburg Thalmann & Co. Buy   Jun 23, '11   3.43  7.00  Jun 23, '12  -5.83%